替吉奥联合伊立替康一线治疗晚期结直肠癌的前瞻性临床观察

目的：观察替吉奥联合伊立替康一线治疗术后复发或转移的晚期结直肠癌的疗效和安全性。方法：42例无手术指征的晚期结直肠癌患者，未接受姑息化疗，接受以下方案作为一线化疗：替吉奥40mg/m2，2次/d，口服，d1～d9；伊立替康180mg/m2，静脉滴注， d1；14d为1个周期（IRIS方案）。对患者进行密切观察和随访。结果：有40例可评价疗效，中位化疗周期数8（4～12），部分缓解14例，稳定22例，疾病进展4例，有效率为45.0%，疾病控制率为90%。中位无进展生存期（PFS）为6.5个月（1.5～10.0个月）。主要毒副作用有皮肤色素沉着、消化道反应和骨髓抑制，多为I～II度，III度以上毒性发生率为7.1%，无治疗相关性死亡。结论：替吉奥联合伊立替康一线治疗晚期结直肠癌，应用方便，近期疗效与目前标准方案相当，毒副反应可耐受。

S-1 plus irinotecan for the first-line treatment of patients with metastatic colorectal cancer:a prospective clinical observation

Objective: To investigate the efficacy and safety of S-1 combined with irinotecan (IRIS) as the first-line chemotherapy for advanced colorectal carcinomas (CRC) with relapse or metastases. Methods:We carried out a cohort study evaluated the efficacy and safety of IRIS as first-line therapy in patients with advanced CRC. Forty-two eligible patients with previously untreated advanced CRC received irinotecan 180mg/m2 followed by S-1 80mg/m2 per day from day 1 to 9 every 2 weeks. The patients were followed intensively. Results:Forty patients were evaluated; the objective response rate was 45.0% (14/40 patients with partial response) in the treated population. Stable disease were observed in 22/40 (55.0%) patients, disease control rate was achieved in 90.0% of all patients. The median progression-free survival (PFS) was 6.5 months (1.5~10.0months).The main toxicities including skin pigmentation, gastrointestinal reactions and bone marrow suppression. Grade 3/4 adverse events were occurred in 3 cases (7.5%). There were no treatment-related deaths occurred. Conclusions:The IRIS regimen demonstrated an similar antitumor activity with present standard regimens. IRIS has well compliance and was well tolerated in patients with untreated advanced CRC. There was warranted to research IRIS combined with target therapy.